Table 1.
Baseline demographic and clinical characteristics for the 2009 acute coronary syndrome population.
| Angiography performed (n = 16 204, 68%) |
No angiography performed (n = 7703, 32%) |
|||||
|---|---|---|---|---|---|---|
| Clopidogrel (n = 12 596, 78%) | Prasugrel (n = 14, <1%) | No DAPT (n = 3594, 22%) | Clopidogrel (n = 3359, 43%) | Prasugrel (n = 0) | No DAPT (n = 4344, 56%) | |
| Age (years) | ||||||
| Mean (SD) | 67.1 (11.3) | 63.9 (11.5) | 68.0 (10.3) | 80.5 (9.5) | – | 82.9 (9.5) |
| Median | 67 | 64 | 69 | 83 | – | 85 |
| Age groups (%) | ||||||
| 18–49 years | 915 (7.3) | 1 (7.1) | 194 (5.4) | 29 (0.9) | – | 36 (0.8) |
| 50–64 years | 4212 (33.4) | 7 (50.0) | 1055 (29.4) | 236 (7.0) | – | 216 (5.0) |
| 65–69 years | 1963 (15.6) | 2 (14.3) | 638 (17.8) | 174 (5.2) | – | 149 (3.4) |
| 70–74 years | 1914 (15.2) | 2 (14.3) | 647 (18.0) | 272 (8.1) | – | 249 (5.7) |
| 75–79 years | 1713 (13.6) | 1 (7.1) | 598 (16.6) | 426 (12.7) | – | 462 (10.6) |
| 80–84 years | 1294 (10.3) | 1 (7.1) | 342 (9.5) | 887 (26.4) | – | 964 (22.2) |
| 85 + years | 585 (4.6) | – | 120 (3.3) | 1335 (39.7) | – | 2268 (52.2) |
| Gender (%) | ||||||
| Men | 8765 (69.6) | 12 (85.7) | 2437 (67.8) | 1769 (52.7) | – | 2043 (47.0) |
| Women | 3831 (30.4) | 2 (14.3) | 1157 (32.2) | 1590 (47.3) | – | 2301 (53.0) |
| Qualifying ACS event (index event) (%) | ||||||
| NSTE ACS (Unstable angina pectoris, NSTEMI) | 6871 (54.5) | 5 (35.7) | 2617 (72.8) | 1892 (56.3) | – | 2362 (54.4) |
| ST segment elevation myocardial infarction | 3508 (27.9) | 8 (57.1) | 430 (12.0) | 306 (9.1) | – | 260 (6.0) |
| Myocardial infarction not sub classified | 2217 (17.6) | 1 (7.1) | 547 (15.2) | 1161 (34.6) | 1722 (39.6) | |
| Invasively treated (%) | ||||||
| PCI | 10211 (81.1) | 14 (100.0) | 675 (18.8) | – | – | – |
| CABG | 244 (1.9) | – | 1721 (47.9) | – | – | – |
| Comorbidity
a
(%) | ||||||
| Previous myocardial infarction(s) | 2097 (16.6) | 4 (28.6) | 590 (16.4) | 1263 (37.6) | – | 1531 (35.2) |
| Previous unstable angina pectoris | 1207 (9.6) | 2 (14.3) | 358 (10.0) | 494 (14.7) | – | 560 (12.9) |
| Previous PCI | 1961 (15.6) | 3 (21.4) | 463 (12.9) | 504 (15.0) | – | 400 (9.2) |
| Previous CABG | 530 (4.2) | – | 130 (3.6) | 221 (6.6) | – | 249 (5.7) |
| Heart failure | 912 (7.2) | 1 (7.1) | 439 (12.2) | 942 (28.0) | – | 1547 (35.6) |
| Peripheral arterial disease | 134 (1.1) | 1 (7.1) | 48 (1.3) | 410 (12.2) | – | 511 (11.8) |
| Stroke (ischeamic and non-ischaemic) | 1028 (8.2) | 1 (7.1) | 424 (11.8) | 752 (22.4) | – | 1060 (24.4) |
| Atrial fibrillation | 918 (7.3) | 1 (7.1) | 486 (13.5) | 624 (18.6) | – | 100 (2.3) |
| Chronic renal dysfunction | 674 (1.4) | 18 (0.9) | 303 (2.0) | 69 (2.1) | – | 476 (3.2) |
| Diabetes | 2229 (17.7) | 4 (28.6) | 829 (23.1) | 940 (28.0) | – | 1114 (25.6) |
| Major bleeding | 546 (4.3) | 1 (7.1) | 216 (6.0) | 298 (8.9) | – | 637 (14.7) |
| Moderate and severe liver disease | 54 (0.4) | – | 20 (0.6) | 21 (0.6) | – | 53 (1.2) |
| Bleeding diathesis/coagulation disease | 85 (0.7) | – | 31 (0.9) | 38 (1.1) | – | 89 (2.0) |
| Cancer | 1484 (11.8) | 1 (7.1) | 457 (12.7) | 709 (21.1) | – | 1003 (23.1) |
| Drugs at discharge (%) | ||||||
| ACE inhbitor/ARB | 10094 (80.1) | 13 (92.9) | 2424 (67.4) | 2506 (74.6) | – | 2715 (62.5) |
| Acetylsalicylic acid | 12548 (99.6) | 14 (100.0) | 2682 (74.6) | 3328 (99.1) | – | 3353 (77.2) |
| Beta-blocker | 11726 (93.1) | 14 (100.0) | 2979 (82.9) | 3006 (89.5) | – | 3512 (80.8) |
| Statins | 12085 (95.9) | 14 (100.0) | 2916 (81.1) | 2412 (71.8) | – | 2106 (48.5) |
| Calcium channel blocker | 3444 (27.3) | 6 (42.9) | 1147 (31.9) | 1244 (37.0) | – | 1396 (32.1) |
| Antidiabetic drugs | 2183 (17.3) | 4 (28.6) | 1573 (43.8) | 1449 (43.1) | – | 940 (21.6) |
| Proton pump inhibitor | 3670 (29.1) | 5 (35.7) | 1224 (34.1) | 1296 (38.6) | – | 1893 (43.6) |
| Warfarin/new OAC | 685 (5.4) | – | 651 (18.1) | 147 (4.4) | – | 769 (17.7) |
SD: standard deviation; ACS: acute coronary syndrome; NSTE: non-ST-segment elevation; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; OAC: oral anticoagulant.
a
Data prior index ACS episode.